AMS HP eNews Bulletin 29 August 2016


  Australasian Menopause Society  
Health Professionals eNews29 August 2016
  Welcome to AMS HP eNews for doctors and other healthcare professionals who have a special interest in women's health. The content covers information and resources relevant to menopause, midlife and the promotion of healthy ageing.


20th AMS Congress - Registration now open 

AMS Annual Congress  Fremantle - Western Australia 18-20 November 2016Attend our Congress at the Esplanade Hotel in Fremantle, right in the heart of the art and cafe culture of the historic port city and close by to beaches, the Swan river and Rottnest Island. 


Register now

Earlybird registration is open until
15 September


Submit an abstract!

AMS invites the submission of papers on original work for consideration for the Congress Program. Authors are invited to submit abstracts for 15 minute oral and/or poster presentations for consideration by the AMS Scientific Program Committee. 


Abstracts may be submitted on any topic relevant to the menopause and its treatment. A link to Guidelines in Preparing and formatting your abstract are available from the AMS Website.


Abstract submissions extended to 15 September 2016



AMS Congress Awards and Scholarships 

At the AMS Congress the following awards will be made: 


Congress Awards 

The Jean Hailes Memorial Prize is presented to the best free communication or poster presentation by a current AMS member who is still within 10 years of having completed their tertiary degree. The presenter is to indicate their eligibility for this prize when submitting their abstract. The winner will receive a certificate of honour and AUD$500.


The Barbara Gross Award is presented to the best overall free communication or poster by a current AMS member. All free communications and posters presented at the Congress by a current AMS member will be entered for this award. The winner will receive a certificate of honour and AUD$1,000.


The Vivien Wallace Poster Prize is given to encourage delegates working in any area of medicine to submit a poster for inclusion in the 2016 Congress program. This is an annual award to the value of AUD$250.


Judges for the Congress Awards are appointed by the Chair of the Scientific Program Committee and there are two judges per room, with a prescribed scoring system.

AMS Awards 

The AMS Scientific Award is given to the most meritorious contribution to the field of menopause by an Australian or New Zealand investigator. This is an annual award based on a published/accepted paper in the past 12 months accepted and in press by 30 June 2016. The paper should be on a specific subject related to menopause. The winner will receive a certificate of honour and AUD$500.00. Applications for the Award should reach the AMS Secretariat by 30 September 2016



AMS Scholarships 

The AMS is pleased to announce that it has agreed to fund five (5) scholarships for medical students, doctors in training or PhD candidates to attend the 20th AMS Congress in Perth. Preference will be given to applicants who submit an abstract to present at the Congress.


The scholarship includes:

  • Full registration to the 20th AMS Annual Congress 2016 including
    - Entry to all Congress sessions
    - Name Badge
    - Satchel o Program Book
    - Morning and Afternoon Tea, Lunches (for all days)
    - Cocktail Function (Friday)
  • One (1) year AMS membership with full member benefits including:
    - Full access to member’s information and resources;
    - Monthly e-news bulletins with latest information from journals, conferences and the media;
    - Quarterly Changes magazine; o Discounts to AMS education and events; and o Access -to the ‘Find a Doctor’ service (if appropriate).

To be eligible for the scholarship applicants must: 

  • Be either a medical student, PhD candidate or a doctor in training;
  • Complete the AMS Scholarship Application Form;
  • Provide a letter of support from their supervisor with their application;
  • Provide a presentation to their supervisor or peer group on highlights of the 20th AMS Congress.

Application forms are to be provided by post or email:

PO BOX 511
Inverloch VIC 3996

Applications must be received by cob Friday 9 September 2016. All applicants will be notified by email when applications are received. All applicants will be notified by email of the outcome of their application by Thursday 15 September 2016



Menopausal hormone therapy and risk of breast cancer  

checking online

The International Menopause Society welcomes the release of this study, published in the British Journal of Cancer, Menopausal hormone therapy and breast cancer: what is the true size of the increased risk? which reinforces the advice provided in our evidence based IMS Recommendations and in the recently published Global Consensus Statement.


Professor Rodney Baber, IMS President comments "This prospective Observational study has attempted to correct for risk of breast cancer associated with MHT use by updating user status at several points during the period of observation.


The study shows an increased risk of breast cancer (or preinvasive DCIS) for women using combined E+P MHT after more than 5 years of treatment and also that this risk increases with prolonged treatment.


There was no increased risk of breast cancer seen for users of oestrogen only therapy.


This data is the same as that reported in the prospective RCT, The Women's Health Initiative, which also found no increased risk for oestrogen only MHT users and a small increase in absolute risk for users of combined MHT comprised of conjugated oestrogen's and medroxyprogesterone acetate.


This new observational study has not differentiated between the various combined MHT regimens nor between different progestogens used.


This is an important oversight as there is considerable evidence to suggest that certain synthetic progestins, such as medroxyprogesterone acetate, may increase breast cancer risk when used in combined MHT when compared to regimens in which micronised progesterone is used.


This new observational study reported no effect on risk for past users of MHT irrespective of the duration of use, and no difference for breast cancer hormone receptor status or morphological type"


Professor Baber concludes "This new observational study, with the best of intentions, remains an observational study with small numbers of breast cancer cases and dose not change our overall understanding of the relationship between MHT use and breast Cancer risk"...




Calcium supplementation and dementia risk   

A small Swedish study on calcium supplementation showed that use may increase the risk of developing dementia in elderly women with cerebrovascular disease.


The study included 700 women aged over 70 without dementia, 98 of whom were taking calcium supplements (we assume due to concerns about osteoporosis, though this was not discussed in the study). After five years, 14.3% of women who'd taken supplements had developed dementia, compared to 7.5% of women who didn't – about double the risk, after taking other factors into account. Further analysis showed that the raised risk only applied to women who had already had a stroke, or who had signs of damage to blood vessels in their brain on scans.


However, this was based on just six out of 15 women with a history of stroke and 50 out of 316 with signs of blood vessel damage who had taken calcium supplements.



Migraine and cardiovascular risk in the menopause  

Long ago it was perceived that migraineurs have a higher risk for ischemic stroke, mainly because of short-term pro-thrombotic alterations during attacks [1, 2]. Migraine with aura confers a lifelong 2–2.5-fold elevated risk of stroke. Frequency of migraine directly correlates with higher stroke risk, but only minimal evidence supports reducing migraine frequency with medications to reduce stroke risk. Women suffering from migraine with aura who smoke have a 9-fold increased risk of stroke. There are several potential mechanisms for the increased risk of ischemic stroke in migraineurs. Migraine may increase ischemic stroke risk via vasospasm-induced cerebrovascular hypoperfusion, platelet activation, increased platelet aggregation, and increased concentrations and activity of various vascular pro-coagulant factors. Still, the absolute risk of migraine-associated stroke in women is relatively low... 


...Women with frequent migraines should be evaluated for other cardiovascular risk factors, and risk reduction strategies should be implemented whenever appropriate. When postmenopausal hormone replacement (HT) is considered, and in view of the higher risk for stroke related to HT, especially in women with migraine and aura, perhaps the lower effective doses and the less thrombogenic hormonal preparations, i.e. transdermal estrogen, should be preferred... 



Join AMS for Member's only content

See exclusive commentary on studies such as:  


Anti-Müllerian hormone and prediction of age at natural menopause

Since the timing of the onset of the last menstrual period in a woman's life varies, less between cultures, but more individually, it has induced a universal challenge on how to predict the age at natural menopause (ANM). Fertility issues in women raise concerns for those who postpone their reproduction due to educational and professional goals. Anti-Müllerian hormone (AMH) seems to have a certain predictive role not only in ANM, ovarian reserve tests, premature ovarian insufficiency, assisted reproduction techniques but also in different clinical conditions such as polycystic ovary syndrome, ovarian surgery, granulosa cell tumors, cancer treatment, anorexia nervosa...


Breast cancer incidence and changes in use of menopausal hormone therapy in European countries

Since the first publication of results from the randomized controlled trial by the Women’s Health Initiative (WHI) [1], consumption of menopausal hormone therapy (MHT) has decreased in most countries [2]. Several studies have reported a coincidental decrease in incidence of breast cancer (BC), but the extent of this decrease and the length of time between the drop in MHT use and the change in BC incidence have varied between countries [3]. This may reflect differences between studies, in BC incidence, in MHT use (prevalence of use and regimens used), in confounding factors (i.e. BC screening), but also in study methodology. We recently published the results of a study, 'Menopausal hormone therapy use in relation to BC incidence in 11 European countries', whose aim was to analyze the changes in BC incidence and MHT use, using the same methodology...


Association of alcohol consumption with the onset of natural menopause: a systematic review and meta-analysis

Although alcohol intake has been suggested to affect the age at which natural menopause occurs, results from observational studies are not consistent. In this systematic review, we aimed to quantify the association between all levels of alcohol consumption and menopause onset. Six electronic databases (Medline, Embase, Cochrane, PubMed, Google Scholar and Web of Science) were systematically searched until 4 November 2015 to identify relevant studies assessing the association between alcohol consumption and onset of menopause. ...


2016 ams congress 1

  Australasian Menopause Society
PO Box 511, Inverloch VIC 3996
Tel: +61 3 9428 8738

  Join the Australasian Menopause Society  
Forward this email to a friend